Ir para o conteúdo principal

Exicure (NASDAQ: XCUR) — Perfil da empresa, notícias e dados financeiros

Logo de Exicure
XCUR Exicure
Exicure primary media
Perfil da empresa

Exicure

Exicure (NASDAQ:XCUR) is a pioneering biotechnology firm deeply engaged in the design and development of therapeutics based on its proprietary spherical nucleic acid (SNA™) technology. These advanced therapeutics have a wide range of applications, including gene regulation and immunotherapy. Exicure's main goal is to harness the power of SNA to unlock new possibilities in the treatment of diseases with genetic origins or for which traditional approaches have been inadequate. The company focuses on advancing its pipeline of innovative treatments through rigorous clinical trials, with the aim of addressing unmet medical needs and improving patient care. By pushing the boundaries of science and technology, Exicure strives to make a significant impact on medicine and healthcare.

Resumo

Public USParticipação acionária
2011Ano de fundação
7Funcionários
Chicago, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Exicure

  • Spherical Nucleic Acids (SNA) technology for precision medicine, targeting genetic diseases.
  • Development of cavrotolimod (AST-008) as an immuno-oncology therapeutic for solid tumors and lymphomas.
  • Collaboration on hair loss treatment focusing on androgenetic alopecia.
  • Research into neurological disorder treatments, including Huntington's and Parkinson's diseases.
  • Partnerships for dermatological applications of SNA technology, addressing psoriasis and atopic dermatitis.
  • Exploration of COVID-19 therapies utilizing proprietary SNA technology.

equipe executiva do Exicure

  • Jungsoo KimCEO, President & Director
  • Gyuyeob LeeInterim CFO & Secretary
  • Young Seung KoChief Operating Officer
  • Joshua MillerChief Accounting Officer
  • Devki SukhtankarHead of Preclinical Research & Translational Medicine
  • Niña CaculitanHead of Clinical

Principais indicadores financeiros

Resultados divulgados pela Exicure, em USD.

Cap. de mercado
6,7 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-1.3
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Exicure
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-10,1 mi-4,9 mi
500 mil-12,2 mi-9,7 mi
0-15 mi-16,9 mi
28,8 mi-1,8 mi-2,6 mi